A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 6144-6152

  Martens, Tobias ^a   Schmidt, Nils Ole ^a   Eckerich, Carmen ^a   Filibrandt, Regina ^a   Merchant, Mark ^b   Schwall, Ralph ^b   Westphal, Manfred ^a   Lamszus, Katrin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; FIBRONECTIN; LAMININ; OA 5 D 5; SCATTER FACTOR RECEPTOR; TENASCIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INFUSION; DRUG INHIBITION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; MICROARRAY ANALYSIS; OSMOTIC MINIPUMP; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES; CELL DIVISION; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; TRANSPLANTATION, HETEROLOGOUS;

EID: 33750683969     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1418     Document Type: Article

References (36)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 2005;7:436-51.
3. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999;17:517-30.
4. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15:49-51.
5. Rosen EM, Laterra J, Joseph A, et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996;67:248-55.
6. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57:5391-8.
7. Moriyama T, Kataoka H, Kawano H et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas, and schwannomas in humans. Cancer Lett 1998;124:149-55.
8. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor, and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-8.
9. Laterra J, Nam M, Rosen E, et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997;76:565-77.
10. Lamszus K, Schmidt NO, Jin L, et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 1998;75:19-28.
11. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98:7443-8.
12. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.
13. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8.
14. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111:237-47.
15. Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis δ viruses. Nat Med 2000;6:327-31.
16. Nguyen TH, Loux N, Dagher I, et al. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther 2003;10:840-9.
17. Wessel D, Flugge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984;138:141-3.
18. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-8.
19. Brockmann MA, Papadimitriou A, Brandt M, Filibrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 2003;9:4578-85.
20. Moriyama T, Kataoka H, Hamasuna R, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 1998;249:73-7.
21. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381-90.
22. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-80.
23. Westphal M, Tonn JC, Ram Z, editors. Local therapies for glioma: present status and future developments. Wien (NY): Springer; 2003.
24. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91:1548-56.
25. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-10.
26. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
27. Jiang WG, Hiscox SE, Parr C, et al. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 1999;5:3695-703.
28. Guerin C, Luddy C, Abounader R, Lal B, Laterra J. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun 2000;273:287-93.
29. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000;60:4277-83.
30. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene 2000;19:2212-23.
31. Brockmann MA, Ulbricht U, Gruner K, Filibrandt R, Westphal M, Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003;52:1391-9.
32. Moriyama T, Kataoka H, Hamasuna R, et al. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and u PA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin Exp Metastasis 1999;17:873-9.
33. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995;270:603-11.
34. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54:3656-61.
35. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
36. Rosen EM, Lamszus K, Laterra J, Polverini PJ, Rubin JS, Goldberg ID. HGF/SF in angiogenesis. Ciba Found Symp 1997;212:215-26.